Nephron Number Determines Susceptibility to Renal Mass Reduction-induced CKD in Lewis and Fisher 344 Rats: Implications for Development of Experimentally Induced Chronic Allograft Nephropathy
Overview
Nephrology
Affiliations
Background: The Fisher 344 (F344) rat kidney transplanted to a Lewis rat recipient is a common model of chronic renal allograft nephropathy (CAN); however, CAN does not develop when the Lewis kidney is grafted into a F344 recipient. In this study we investigated whether a difference in nephron number/glomerular volume exists between the strains that could contribute to a greater susceptibility to development of kidney disease in the F344.
Methods: Separate animals, male F344 and Lewis rats, were subjected to either sham surgery or right uni-nephrectomy and infarction of 2/3 of the left kidney, to produce a 5/6 ablation/infarction injury (5/6 A/I). Serial urinary protein excretions were measured, a terminal 24-h creatinine clearance was obtained and rats were killed 11 weeks after surgery and kidneys were harvested for pathology. Glomerular volumes were measured in the sham controls of each strain. Glomerular number was counted in separate, normal rats of each strain.
Results: The normal F344 had approximately 30% fewer glomeruli than Lewis rats that were larger in volume. The sham F344 had similar creatinine clearance and glomerular structure to the Lewis shams, although BP and urine protein excretion were higher. After 5/6 A/I the F344 developed more severe proteinuria and structural kidney damage. When factored for kidney weight, the F344 rats exhibited a greater compensatory hyperfiltration in response to 5/6 A/I, compared to Lewis.
Conclusions: The F344 strain is more vulnerable to development of progressive kidney damage due to 5/6 A/I, compared to the Lewis. This is likely due to the lower nephron number/greater glomerular volume of the F344 that may also account for the greater susceptibility to CAN exhibited by this strain.
The Influence of Donor to Recipient Size Matching on Kidney Transplant Outcomes.
Arshad A, Hodson J, Chappelow I, Nath J, Sharif A Transplant Direct. 2018; 4(10):e391.
PMID: 30498768 PMC: 6233665. DOI: 10.1097/TXD.0000000000000826.
Deng A, Conrad K, Baylis C Am J Physiol Regul Integr Comp Physiol. 2017; 314(2):R147-R152.
PMID: 29046312 PMC: 5867670. DOI: 10.1152/ajpregu.00148.2017.
The Impact of Kidney Development on the Life Course: A Consensus Document for Action.
Nephron. 2017; 136(1):3-49.
PMID: 28319949 PMC: 5472217. DOI: 10.1159/000457967.
Comparative effects of mesenchymal stem cell therapy in distinct stages of chronic renal failure.
Caldas H, de Paula Couto T, Fernandes I, Baptista M, Kawasaki-Oyama R, Goloni-Bertollo E Clin Exp Nephrol. 2015; 19(5):783-9.
PMID: 25630669 DOI: 10.1007/s10157-015-1079-1.
Severe renal mass reduction impairs recovery and promotes fibrosis after AKI.
Polichnowski A, Lan R, Geng H, Griffin K, Venkatachalam M, Bidani A J Am Soc Nephrol. 2014; 25(7):1496-507.
PMID: 24511135 PMC: 4073422. DOI: 10.1681/ASN.2013040359.